
|Articles|January 4, 2022
Daily Medication Pearl: Rivaroxaban (Xarelto)
Author(s)Saro Arakelians, PharmD
Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis, and pulmonary embolism.
Advertisement
Medication Pearl of the Day: Rivaroxaban (Xarelto)
Indication: Rivaroxaban is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and of PE, and for the prophylaxis of DVT that may lead to PE in patients undergoing knee or hip replacement surgery.
Insight:
- Dosing: Take 15 mg and 20 mg tablets with food. Take 10 mg tablets with or without food.
- Dosage forms: Tablets 10 mg, 15 mg, and 20 mg.
- Adverse events: The most common adverse reaction (>5%) was bleeding.
- Mechanism of action: Rivaroxaban is a selective inhibitor of FXa. It does not require a cofactor (such as anti-thrombin III) for activity.
- Manufacturer: Janssen Pharma
Sources:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
3
Real-World Use of Talazoparib Plus Enzalutamide and HR Testing Trends in Prostate Cancer
4
Oncology Pulse Points: ASCO Living Guideline Updates in Metastatic Castration-Resistant Prostate Cancer
5




























































































































